| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., November 5, 2026 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026. |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Press Release Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights • Reported total revenue of $57 million for the second quarter of 2026 and raised full- year 2026 Revenue Framework • Improved GAAP Combined R... |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Novavax, Inc. (the “Company”) held its Annual Meeting, at which stockholders as of April 23, 2026 (the “Record Date”) were entitled to vote. As of the Record Date, there were 164,427,429 shares of the Company’s common s... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., May 6, 2026 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2026. |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., February 26, 2026 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. |
| 20 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”), collectively (the “Parties”). The License and Option... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
© 2026 NOVAVAX. All rights reserved. 1 Novavax Corporate Presentation John C. Jacobs, President and Chief Executive Officer J.P. Morgan Healthcare Conference © 2026 NOVAVAX. All rights reserved. 1 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., November 6, 2025 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025. |
| 04 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment |
| 22 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Material Impairments +1 more
Certain information identified with [***] has been excluded from the exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
| 07 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment |
| 27 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE dated as of August 27, 2025 between NOVAVAX, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association,... |
| 27 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
Novavax’s Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. |
| 21 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Novavax, Inc., a Delaware corporation, (the “Company”), is offering a new series of its 4.625% Convertible Senior Notes due 2031 (the “New Notes”). The New Notes will be convertible into cash, shares (“Underlying Shares”) of common stock... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., August 6, 2025 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended June 30, 2025. |
| 24 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 20, 2025, Novavax, Inc. (the “Company”) held its Annual Meeting, at which stockholders as of April 21, 2025 (the “Record Date”) were entitled to vote. As of the Record Date, there were 161,968,503 shares of the Company’s common s... |
| 11 Jun 2025 |
8-K: Regulation FD Disclosure
Goldman Sachs 46 th Annual Global Healthcare Conference June 11, 2025 © 2025 NOVAVAX. All rights reserved. |
| 27 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 27, 2025, the Board of Directors of Novavax, Inc. (the “Company”) determined to eliminate the position of Chief Operating Officer, and terminate the employment of John Trizzino with the Company effective as of June 20, 2025. Mr. T... |
| 19 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Novavax’s multi-year guidance provided in its first quarter 2025 earnings conference call includes the potential impact to Novavax of funding the postmarketing commitment (“PMC”) discussed under “Item 8.01. Other Events” in this Current ... |
Loading...